|
WO2020170215A1
|
|
T cell repertoire dynamics and oncolytic viral therapy
|
|
EP3068411A1
|
|
Oncolytic viruses and increased cancer treatment regimens
|
|
WO2015017915A1
|
|
Methods of treating taxane naïve subjects with primary tumors or with metastatic cancer
|
|
AU2013201835A1
|
|
Reoviruses having modified sequences
|
|
AU2013204555A1
|
|
Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
|
|
MX2013012627A
|
|
Methods of purifying viruses using gel permeation chromatography.
|
|
SG190418A1
|
|
Liquid viral formulations
|
|
EP2646052A2
|
|
Lyophilized viral formulations
|
|
CA2723587A1
|
|
Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
|
|
WO2009143610A1
|
|
Modulating interstitial pressure and oncolytic viral delivery and distribution
|
|
CN101820892A
|
|
Treatment regime for proliferative disorders
|
|
TW200909581A
|
|
Mutant reoviruses and methods of making and using
|
|
CN101627122A
|
|
Reoviruses having modified sequences
|
|
KR20090125103A
|
|
Reoviruses having modified sequences
|
|
AU2007211922A1
|
|
Method of Extracting Virus from Cell Culture
|
|
AU2007202448A1
|
|
Reovirus for the treatment of cellular proliferative disorders
|
|
AU2007215328A1
|
|
Use of local immune suppression to enhance oncolytic viral therapy
|
|
CN101378770A
|
|
Use of local immune suppression to enhance oncolytic viral therapy
|
|
MX2008002743A
|
|
Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms.
|
|
US2006088869A1
|
|
Viral purification methods
|
